Dr. Reddys Laboratories has launched Levalbuterol Inhalation Solution, USP 0.31 mg /3 mL, 0.63 mg /3 mL, 1.25 mg / 3 mL Unit-Dose Vials, a therapeutic equivalent generic version of XOPENEX (levalbuterol hydrochloride) inhalation solution in the US market on September 23, 2014, approved by the United States Food & Drug Administration (USFDA).
Real Time News & Trading Trends Keep Liking #EpicResearch
Facebook – Twitter – YouTube – Pinterest –Linkedin - Google+
For more information ✆ – 0731-6642300 or Visit http://www.epicresearch.co
No comments:
Post a Comment